median UACR 365 mg/g), both balcinrenone doses combined with Dapagliflozin significantly reduced albuminuria compared with dapagliflozin alone
John Sharretts, director of the division of Diabetes, Lipid Disorders and Obesity in the FDAs Center for Drug Evaluation and Research, said in a news release
From a purely pharmacological perspective, the two molecules affect partially different receptors, which explains the theoretical interest of the question
Ultimately, the best choice depends on individual needs, and its important to consult with a healthcare provider to determine the most suitable option
The observed reduction in NNT achieved by the inclusion of additional endpoints beyond the primary endpoint speaks to the limitations of a restricted definition of benefit
Semaglutide reduced the risk of death from cardiovascular causes, nonfatal myocardial infarction, or non-fatal strokes by 20% compared to placebo [45], with a more pronounced risk reduction (26%) in patients with type 2 diabetes [46]